Patent US4789658A successfully refreshed from Google Patents.
US4789658A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Immunoprophylactic and immunotherapeutic agents
Assignee: Ajinomoto Co Inc
•
Filing: 1986-06-09
•
Granted: 1988-12-06
•
Expires: 2006-06-09
Abstract
Abstract An immunopropylactic and immunotherapeutic agent comprising human interleukin 2 of human cellular origin is disclosed along with a method of producing the agent.
Inventors
- 👤 Ryota Yoshimoto
- 👤 Nobukazu Kashima
- 👤 Junji Hamuro
- 👤 Koji Mitsugi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 15:38
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/55; A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K31/716; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61P; A61P35/00
Claims Analysis
Total Claims: 2
Claim 1
Independent Claim
86 words
An immunoprophylactic and immunotherapeutic agent, composition comprising grade E human interleukin 2 of human T-lymphocyte cell origin, which is substantially free from endotoxins and pyrogens and is wholly or partially in the oxidized state, having a specific activity of at least 2×10 5 units/mg protein, said interleukin 2 showing no cytocidal activity against human lymphocytes in vitro at a concentration of 10 5 units/ml and having substantially no other lymphokine or monokine activity, in combination with an amount of lentinan sufficient to exert synergistic immunological activity.
Claim 2
Dependent Claim
86 words
An immunoprophylactic and immunotherapeutic agent, composition comprising grade E human interleukin 2 of human T-lymphocyte cell origin, which is substantially free from endotoxins and pyrogens and is wholly or partially in the oxidized state, having a specific activity of at least 2×10 5 units/mg protein, said interleukin 2 showing no cytocidal activity against human lymphocytes in vitro at a concentration of 10 5 units/ml and having substantially no other lymphokine or monokine activity, in combination with an amount of lentinan sufficient to exert synergistic immunological activity.
References Cited (Backward Citations)
US4359389A
Cited
US4368148A
Cited
US4350687A
Cited
US4390623A
Cited
US4411992A
Cited
US4406830A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-12-06 | 1992-06-06 | 1992-12-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-12-06 | 1996-06-06 | 1996-12-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-12-06 | 2000-06-06 | 2000-12-06 | $7700.00 | Window Closed / Lapsed |